Cardiothoracic & vascular anesthesia
Effect of In Vivo Administration of Fibrinogen Concentrate Versus Cryoprecipitate on Ex Vivo Clot Degradation in Neonates Undergoing Cardiac Surgery
Authors' conclusion
Neonates who received fibrinogen concentrate, as compared to cryoprecipitate, have similar perioperative ex vivo clot degradation with faster degradation at 24 hours postsurgery, less post-CPB blood transfusions, and no increased bleeding or thrombotic complications.
Study context
- Population
- Neonates undergoing cardiac surgery with cardiopulmonary bypass (CPB)ITT
- Participants
- 36 neonates
- Comparison
- Study vs Control
- Studyn = 17
- Controln = 13reference
- Primary endpoint
- Percent change in ex vivo clot degradation from baseline
- Follow-up
- 24 hours after surgery
Methodological detailsinvestigator-initiated
- Investigator-initiated
Primary result
As reported in the abstract
Percent change in ex vivo clot degradation from presurgery baseline (T4) · 24 hours postsurgery
Study
826.5%
95% CI 291.1–1361.9
Control
−545.9%
95% CI −1081.3–-10.4
P < 0.001
Secondary outcomes
Post-CPB transfusions (ITT) · intention-to-treat
P = 0.043
Post-CPB transfusions (PP) · per protocol
P < 0.001
Clot degradation at T2 (after treatment) and T3 (intensive care unit (ICU) arrival)
- No significant differences
Safety
Bleeding or thrombotic events
- No differences observed
Original publication
Effect of In Vivo Administration of Fibrinogen Concentrate Versus Cryoprecipitate on Ex Vivo Clot Degradation in Neonates Undergoing Cardiac Surgery. Anesth Analg. Published 8 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →